Remus Pharmaceuticals Limited — Board Meeting, 17-05-2025: Outcome of Board Meeting

Remus Pharmaceuticals has announced a board meeting on May 17, 2025, approving audited consolidated results for FY25. Revenue soared 191% YoY to Rs. 620.36 Cr, with PAT before minority interest up 58% to Rs. 38.42 Cr. H2 showed strong momentum, growing 27.5% over H1. The Board declared a final dividend of Rs. 0.50/share and approved a 1:1 bonus issue. Leadership changes include Mr. Swapnil Jatinbhai Shah and Mrs. Anar Swapnil Shah stepping down as Whole-Time Directors to become Non-Executive Directors. Plans to open a Singapore branch were also approved.